Financial Lp Hrt Acquires 843,622 Shares of Aditxt (NASDAQ:ADTX) Stock

Aditxt, Inc. (NASDAQ:ADTX) major shareholder Financial Lp Hrt purchased 843,622 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was bought at an average cost of $0.08 per share, for a total transaction of $67,489.76. Following the acquisition, the insider owned 505,302 shares in the company, valued at approximately $40,424.16. The trade was a -249.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Friday, June 5th, Financial Lp Hrt sold 735,462 shares of Aditxt stock. The stock was sold at an average price of $0.06, for a total value of $44,127.72.
• On Friday, April 24th, Financial Lp Hrt sold 1,089 shares of Aditxt stock. The stock was sold at an average price of $7.56, for a total value of $8,232.84.
• On Thursday, April 23rd, Financial Lp Hrt sold 141 shares of Aditxt stock. The stock was sold at an average price of $7.83, for a total value of $1,104.03.
• On Tuesday, April 21st, Financial Lp Hrt bought 2,700 shares of Aditxt stock. The shares were acquired at an average cost of $8.91 per share, for a total transaction of $24,057.00.
• On Wednesday, April 22nd, Financial Lp Hrt sold 443 shares of Aditxt stock. The shares were sold at an average price of $8.10, for a total value of $3,588.30.

Aditxt Price Performance

Shares of Aditxt stock opened at $0.03 on Wednesday. The business’s fifty day moving average price is $6.89 and its two-hundred day moving average price is $158.83. The company has a market capitalization of $23,698.00, a P/E ratio of 0.00 and a beta of 0.84. Aditxt, Inc. has a 1-year low of $0.03 and a 1-year high of $53,451.08.

Aditxt (NASDAQ:ADTX) last announced its earnings results on Tuesday, March 31st. The company reported $315,563.31 earnings per share for the quarter. Aditxt had a negative return on equity of 374.60% and a negative net margin of 360,152.50%.

Analysts Set New Price Targets

Several analysts have weighed in on ADTX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aditxt in a research note on Monday, April 20th. Wall Street Zen raised Aditxt to a “sell” rating in a research note on Saturday, May 23rd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Aditxt currently has an average rating of “Sell”.

Aditxt Company Profile

Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.

The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.